Elite in Prurigo Nodularis

Martin Metz

Berlin, BE, DE 
Elite in Prurigo Nodularis
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Martin Metz practices in Berlin, Germany. Mr. Metz is rated as an Elite expert by MediFind in the treatment of Prurigo Nodularis. His top areas of expertise are Chronic Spontaneous Urticaria (CSU), Hives, Prurigo Nodularis, and Angioedema.

His clinical research consists of co-authoring 243 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 1 clinical trial in the study of Prurigo Nodularis.

Gender
Male

Locations

Berlin, BE, Germany
Other Locations
Muenster, NW 48149, Germany
Bochum, NW 44791, Germany
Hannover, NI, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Proof of Concept, Multicenter, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Cholinergic Urticaria Despite H1-antihistamine Treatment
A Randomized, Double-blind, Placebo-controlled, Proof of Concept, Multicenter, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Cholinergic Urticaria Despite H1-antihistamine Treatment
Enrollment Status: Completed
Publish Date: September 06, 2023
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological
Study Drug: CDX-0159
Study Phase: Phase 1
View 1 Less Clinical Trial

243 Total Publications

Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.
Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.
Journal: Dermatology and therapy
Published: August 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Metz's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile